Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Acute Market Reports | PRODUCT CODE: 1340102

Cover Image

PUBLISHER: Acute Market Reports | PRODUCT CODE: 1340102

Anti-Infective Drugs Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031

PUBLISHED:
PAGES: 112 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 4500
PDF (Multi User License)
USD 6500
PDF (Enterprise License)
USD 9000

Add to Cart

The anti-infective drugs market is expected to witness a CAGR of 3.8% during the forecast period of 2023 to 2031, driven by various factors. Anti-infective drugs, also known as antimicrobial drugs, are used to treat infectious diseases caused by bacteria, viruses, fungi, and parasites. These drugs play a crucial role in combating infections and reducing morbidity and mortality rates associated with infectious diseases. This analysis provides a brief overview of the anti-infective drugs market, followed by an in-depth examination of the three key drivers and one restraint impacting the market. Furthermore, the market is segmented based on drug class and route of administration, along with an exploration of geographic trends and the competitive landscape.

Increasing Prevalence of Infectious Diseases

The rising prevalence of infectious diseases is a major driver contributing to the growth of the anti-infective drugs market. In recent years, the world has witnessed outbreaks of infectious diseases, which have highlighted the importance of effective anti-infective drugs. Infectious diseases continue to pose significant global health challenges, affecting millions of people and driving the demand for anti-infective drugs to combat various infections, including respiratory infections, sexually transmitted diseases, and gastrointestinal infections. The increasing prevalence of healthcare-associated infections has also driven the demand for anti-infective drugs to prevent and treat these infections. This driver is further supported by data from the World Health Organization (WHO), which states that lower respiratory infections, including pneumonia, were the third leading cause of global mortality in 2020, causing over 2.5 million deaths.

Emergence of Antimicrobial Resistance

Antimicrobial resistance (AMR) is a pressing public health concern that has fueled the demand for innovative and effective anti-infective drugs. Overuse and misuse of antimicrobial drugs have led to the development of drug-resistant pathogens, making traditional antibiotics less effective. This has necessitated the development of new anti-infective drugs with novel mechanisms of action to combat drug-resistant infections. Data from the Centers for Disease Control and Prevention (CDC) supports this driver, stating that at least 2.8 million people in the United States are infected with antibiotic-resistant bacteria each year, resulting in over 35,000 deaths. Globally, AMR leads to approximately 700,000 deaths annually, and if left unchecked, this number is expected to rise to 10 million deaths by 2050.

Technological Advancements in Drug Development

Advancements in drug discovery and development have significantly contributed to the growth of the anti-infective drugs market. Innovative technologies, such as genomics, high-throughput screening, and computational modeling, have revolutionized the drug discovery process, leading to the identification of novel drug targets and the development of more effective anti-infective drugs.An example of this driver can be seen in the development of mRNA-based vaccines, such as those used in the COVID-19 vaccines by Pfizer-BioNTech and Moderna. These vaccines have demonstrated high efficacy rates in preventing COVID-19, signaling the potential of mRNA technology in developing new vaccines against other infectious diseases.

Stringent Regulatory Approval Process

The stringent regulatory approval process is a significant restraint in the anti-infective drugs market. Developing new anti-infective drugs involves extensive preclinical and clinical trials to demonstrate safety, efficacy, and the drug's ability to treat specific infections. The regulatory approval process is time-consuming and resource-intensive, leading to delays in drug development and market entry. The average time taken for a new drug to move from the preclinical phase to regulatory approval is approximately 12 years. Additionally, the high failure rate of drugs in clinical trials further prolongs the approval process and adds to the overall cost of drug development.

Market Segmentation by Drug Class

Antibiotics represent the highest revenue-generating segment within the anti-infective drugs market. Antibiotics are a class of drugs used to treat bacterial infections, and they are widely prescribed for various infections, including urinary tract infections, respiratory infections, and skin infections. The global antibiotics market was valued at $43.2 billion in 2022. The increasing prevalence of bacterial infections and the emergence of drug-resistant bacteria have driven the demand for antibiotics. Antiviral drugs demonstrate the highest Compound Annual Growth Rate (CAGR) within the anti-infective drugs market. Antivirals are used to treat viral infections, such as influenza, HIV/AIDS, and hepatitis. The global antiviral drugs market is expected to grow at a CAGR of 7.4% from 2023 to 2031. The increasing incidence of viral infections, coupled with the development of new antiviral therapies, is contributing to the growth of this segment.

Market Segmentation by Route of Administration

Oral administration represents the highest revenue-generating route of administration in the anti-infective drugs market. Oral drugs are convenient for patients and healthcare providers, as they do not require invasive procedures or medical supervision for administration. The oral administration segment dominated the anti-infective drugs market in 2022. The ease of drug delivery, patient compliance, and cost-effectiveness of oral drugs contribute to their widespread adoption.

Geographic Segment

The anti-infective drugs market exhibits regional variations in terms of revenue and CAGR. As of 2022, North America led the market in terms of revenue, driven by advanced healthcare infrastructure, high healthcare expenditure, and the presence of key pharmaceutical companies. However, the Asia Pacific region is expected to witness the highest CAGR during the forecast period from 2023 to 2031. The Asia Pacific region's growing population, increasing awareness about infectious diseases, and expanding healthcare access are key factors contributing to the region's market growth.

Competitive Trends and Key Strategies

The anti-infective drugs market is highly competitive, with several pharmaceutical companies vying for market share. Key players in the market include Pfizer Inc., GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Johnson & Johnson, Gland Pharma Ltd., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Abbott, Astellas Pharma Inc., Alkem Laboratories, AstraZeneca, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Sanofi. These companies focus on strategic initiatives, such as product launches, mergers and acquisitions, and research and development activities, to strengthen their market position.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofAnti-Infective Drugs market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report

Micro and macro environment factors that are currently influencing the Anti-Infective Drugs market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Class

Antibacterials

B-lactams

Quinolones

Macrolides

Tetracycline

Aminoglycoside

Others (Phenicols, Sulfonamides, etc.)

Antivirals

Miscellaneous Antivirals

Adamantane Antivirals

Antiviral Boosters

Others (Antiviral Combinations, Antiviral Interferons, etc.)

Antifungals

Azoles

Echinocandins

Polyenes

Others

Others (Antiparasitics, Anthelmintics, etc.)

Route of Administration

Oral

Parenteral

Others (Topical, etc.)

Indication

Pneumonia

Sepsis

Tuberculosis

Influenza

HIV Infection

Hepatitis Virus Infection

Respiratory Virus Infection

Others (Aspergillosis, Candidiasis, Dermatophytosis, etc.)

Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Region Segment (2021-2031; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Anti-Infective Drugs market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2031.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Anti-Infective Drugs market?

Which is the largest regional market for Anti-Infective Drugs market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Anti-Infective Drugs market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Anti-Infective Drugs market worldwide?

Product Code: 138243-07-23

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Anti-Infective Drugs Market
  • 2.2. Global Anti-Infective Drugs Market, By Drug Class, 2022 (US$ Million)
  • 2.3. Global Anti-Infective Drugs Market, By Route of Administration, 2022 (US$ Million)
  • 2.4. Global Anti-Infective Drugs Market, By Indication, 2022 (US$ Million)
  • 2.5. Global Anti-Infective Drugs Market, By Distribution Channel, 2022 (US$ Million)
  • 2.6. Global Anti-Infective Drugs Market, By Geography, 2022 (US$ Million)
  • 2.7. Attractive Investment Proposition by Geography, 2022

3. Anti-Infective Drugs Market: Competitive Analysis

  • 3.1. Market Positioning of Key Anti-Infective Drugs Market Vendors
  • 3.2. Strategies Adopted by Anti-Infective Drugs Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. Anti-Infective Drugs Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Anti-Infective Drugs Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Anti-Infective Drugs Market: By Drug Class, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. Antibacterials
      • 5.3.1.1. B-lactams
      • 5.3.1.2. Quinolones
      • 5.3.1.3. Macrolides
      • 5.3.1.4. Tetracycline
      • 5.3.1.5. Aminoglycoside
      • 5.3.1.6. Others (Phenicols, Sulfonamides, etc.)
    • 5.3.2. Antivirals
      • 5.3.2.1. Miscellaneous Antivirals
      • 5.3.2.2. Adamantane Antivirals
      • 5.3.2.3. Antiviral Boosters
      • 5.3.2.4. Others (Antiviral Combinations, Antiviral Interferons, etc.)
    • 5.3.3. Antifungals
      • 5.3.3.1. Azoles
      • 5.3.3.2. Echinocandins
      • 5.3.3.3. Polyenes
      • 5.3.3.4. Others
    • 5.3.4. Others (Antiparasitics, Anthelmintics, etc.)

6. Anti-Infective Drugs Market: By Route of Administration, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 6.3. Market Segmentation
    • 6.3.1. Oral
    • 6.3.2. Parenteral
    • 6.3.3. Others (Topical, etc.)

7. Anti-Infective Drugs Market: By Indication, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 7.3. Market Segmentation
    • 7.3.1. Pneumonia
    • 7.3.2. Sepsis
    • 7.3.3. Tuberculosis
    • 7.3.4. Influenza
    • 7.3.5. HIV Infection
    • 7.3.6. Hepatitis Virus Infection
    • 7.3.7. Respiratory Virus Infection
    • 7.3.8. Others (Aspergillosis, Candidiasis, Dermatophytosis, etc.)

8. Anti-Infective Drugs Market: By Distribution Channel, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 8.3. Market Segmentation
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies

9. North America Anti-Infective Drugs Market, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. Anti-Infective Drugs Market: By Drug Class, 2021-2031, USD (Million)
  • 9.3. Anti-Infective Drugs Market: By Route of Administration, 2021-2031, USD (Million)
  • 9.4. Anti-Infective Drugs Market: By Indication, 2021-2031, USD (Million)
  • 9.5. Anti-Infective Drugs Market: By Distribution Channel, 2021-2031, USD (Million)
  • 9.6.Anti-Infective Drugs Market: By Region, 2021-2031, USD (Million)
    • 9.6.1.North America
      • 9.6.1.1. U.S.
        • 9.6.1.1.1. Anti-Infective Drugs Market: By Drug Class, 2021-2031, USD (Million)
        • 9.6.1.1.2. Anti-Infective Drugs Market: By Route of Administration, 2021-2031, USD (Million)
        • 9.6.1.1.3. Anti-Infective Drugs Market: By Indication, 2021-2031, USD (Million)
        • 9.6.1.1.4. Anti-Infective Drugs Market: By Distribution Channel, 2021-2031, USD (Million)
      • 9.6.1.2. Canada
        • 9.6.1.2.1. Anti-Infective Drugs Market: By Drug Class, 2021-2031, USD (Million)
        • 9.6.1.2.2. Anti-Infective Drugs Market: By Route of Administration, 2021-2031, USD (Million)
        • 9.6.1.2.3. Anti-Infective Drugs Market: By Indication, 2021-2031, USD (Million)
        • 9.6.1.2.4. Anti-Infective Drugs Market: By Distribution Channel, 2021-2031, USD (Million)
      • 9.6.1.3. Rest of North America
        • 9.6.1.3.1. Anti-Infective Drugs Market: By Drug Class, 2021-2031, USD (Million)
        • 9.6.1.3.2. Anti-Infective Drugs Market: By Route of Administration, 2021-2031, USD (Million)
        • 9.6.1.3.3. Anti-Infective Drugs Market: By Indication, 2021-2031, USD (Million)
        • 9.6.1.3.4. Anti-Infective Drugs Market: By Distribution Channel, 2021-2031, USD (Million)

10. UK and European Union Anti-Infective Drugs Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. Anti-Infective Drugs Market: By Drug Class, 2021-2031, USD (Million)
  • 10.3. Anti-Infective Drugs Market: By Route of Administration, 2021-2031, USD (Million)
  • 10.4. Anti-Infective Drugs Market: By Indication, 2021-2031, USD (Million)
  • 10.5. Anti-Infective Drugs Market: By Distribution Channel, 2021-2031, USD (Million)
  • 10.6.Anti-Infective Drugs Market: By Region, 2021-2031, USD (Million)
    • 10.6.1.UK and European Union
      • 10.6.1.1. UK
        • 10.6.1.1.1. Anti-Infective Drugs Market: By Drug Class, 2021-2031, USD (Million)
        • 10.6.1.1.2. Anti-Infective Drugs Market: By Route of Administration, 2021-2031, USD (Million)
        • 10.6.1.1.3. Anti-Infective Drugs Market: By Indication, 2021-2031, USD (Million)
        • 10.6.1.1.4. Anti-Infective Drugs Market: By Distribution Channel, 2021-2031, USD (Million)
      • 10.6.1.2. Germany
        • 10.6.1.2.1. Anti-Infective Drugs Market: By Drug Class, 2021-2031, USD (Million)
        • 10.6.1.2.2. Anti-Infective Drugs Market: By Route of Administration, 2021-2031, USD (Million)
        • 10.6.1.2.3. Anti-Infective Drugs Market: By Indication, 2021-2031, USD (Million)
        • 10.6.1.2.4. Anti-Infective Drugs Market: By Distribution Channel, 2021-2031, USD (Million)
      • 10.6.1.3. Spain
        • 10.6.1.3.1. Anti-Infective Drugs Market: By Drug Class, 2021-2031, USD (Million)
        • 10.6.1.3.2. Anti-Infective Drugs Market: By Route of Administration, 2021-2031, USD (Million)
        • 10.6.1.3.3. Anti-Infective Drugs Market: By Indication, 2021-2031, USD (Million)
        • 10.6.1.3.4. Anti-Infective Drugs Market: By Distribution Channel, 2021-2031, USD (Million)
      • 10.6.1.4. Italy
        • 10.6.1.4.1. Anti-Infective Drugs Market: By Drug Class, 2021-2031, USD (Million)
        • 10.6.1.4.2. Anti-Infective Drugs Market: By Route of Administration, 2021-2031, USD (Million)
        • 10.6.1.4.3. Anti-Infective Drugs Market: By Indication, 2021-2031, USD (Million)
        • 10.6.1.4.4. Anti-Infective Drugs Market: By Distribution Channel, 2021-2031, USD (Million)
      • 10.6.1.5. France
        • 10.6.1.5.1. Anti-Infective Drugs Market: By Drug Class, 2021-2031, USD (Million)
        • 10.6.1.5.2. Anti-Infective Drugs Market: By Route of Administration, 2021-2031, USD (Million)
        • 10.6.1.5.3. Anti-Infective Drugs Market: By Indication, 2021-2031, USD (Million)
        • 10.6.1.5.4. Anti-Infective Drugs Market: By Distribution Channel, 2021-2031, USD (Million)
      • 10.6.1.6. Rest of Europe
        • 10.6.1.6.1. Anti-Infective Drugs Market: By Drug Class, 2021-2031, USD (Million)
        • 10.6.1.6.2. Anti-Infective Drugs Market: By Route of Administration, 2021-2031, USD (Million)
        • 10.6.1.6.3. Anti-Infective Drugs Market: By Indication, 2021-2031, USD (Million)
        • 10.6.1.6.4. Anti-Infective Drugs Market: By Distribution Channel, 2021-2031, USD (Million)

11. Asia Pacific Anti-Infective Drugs Market, 2021-2031, USD (Million)

  • 11.1. Market Overview
  • 11.2. Anti-Infective Drugs Market: By Drug Class, 2021-2031, USD (Million)
  • 11.3. Anti-Infective Drugs Market: By Route of Administration, 2021-2031, USD (Million)
  • 11.4. Anti-Infective Drugs Market: By Indication, 2021-2031, USD (Million)
  • 11.5. Anti-Infective Drugs Market: By Distribution Channel, 2021-2031, USD (Million)
  • 11.6.Anti-Infective Drugs Market: By Region, 2021-2031, USD (Million)
    • 11.6.1.Asia Pacific
      • 11.6.1.1. China
        • 11.6.1.1.1. Anti-Infective Drugs Market: By Drug Class, 2021-2031, USD (Million)
        • 11.6.1.1.2. Anti-Infective Drugs Market: By Route of Administration, 2021-2031, USD (Million)
        • 11.6.1.1.3. Anti-Infective Drugs Market: By Indication, 2021-2031, USD (Million)
        • 11.6.1.1.4. Anti-Infective Drugs Market: By Distribution Channel, 2021-2031, USD (Million)
      • 11.6.1.2. Japan
        • 11.6.1.2.1. Anti-Infective Drugs Market: By Drug Class, 2021-2031, USD (Million)
        • 11.6.1.2.2. Anti-Infective Drugs Market: By Route of Administration, 2021-2031, USD (Million)
        • 11.6.1.2.3. Anti-Infective Drugs Market: By Indication, 2021-2031, USD (Million)
        • 11.6.1.2.4. Anti-Infective Drugs Market: By Distribution Channel, 2021-2031, USD (Million)
      • 11.6.1.3. India
        • 11.6.1.3.1. Anti-Infective Drugs Market: By Drug Class, 2021-2031, USD (Million)
        • 11.6.1.3.2. Anti-Infective Drugs Market: By Route of Administration, 2021-2031, USD (Million)
        • 11.6.1.3.3. Anti-Infective Drugs Market: By Indication, 2021-2031, USD (Million)
        • 11.6.1.3.4. Anti-Infective Drugs Market: By Distribution Channel, 2021-2031, USD (Million)
      • 11.6.1.4. Australia
        • 11.6.1.4.1. Anti-Infective Drugs Market: By Drug Class, 2021-2031, USD (Million)
        • 11.6.1.4.2. Anti-Infective Drugs Market: By Route of Administration, 2021-2031, USD (Million)
        • 11.6.1.4.3. Anti-Infective Drugs Market: By Indication, 2021-2031, USD (Million)
        • 11.6.1.4.4. Anti-Infective Drugs Market: By Distribution Channel, 2021-2031, USD (Million)
      • 11.6.1.5. South Korea
        • 11.6.1.5.1. Anti-Infective Drugs Market: By Drug Class, 2021-2031, USD (Million)
        • 11.6.1.5.2. Anti-Infective Drugs Market: By Route of Administration, 2021-2031, USD (Million)
        • 11.6.1.5.3. Anti-Infective Drugs Market: By Indication, 2021-2031, USD (Million)
        • 11.6.1.5.4. Anti-Infective Drugs Market: By Distribution Channel, 2021-2031, USD (Million)
      • 11.6.1.6. Rest of Asia Pacific
        • 11.6.1.6.1. Anti-Infective Drugs Market: By Drug Class, 2021-2031, USD (Million)
        • 11.6.1.6.2. Anti-Infective Drugs Market: By Route of Administration, 2021-2031, USD (Million)
        • 11.6.1.6.3. Anti-Infective Drugs Market: By Indication, 2021-2031, USD (Million)
        • 11.6.1.6.4. Anti-Infective Drugs Market: By Distribution Channel, 2021-2031, USD (Million)

12. Latin America Anti-Infective Drugs Market, 2021-2031, USD (Million)

  • 12.1. Market Overview
  • 12.2. Anti-Infective Drugs Market: By Drug Class, 2021-2031, USD (Million)
  • 12.3. Anti-Infective Drugs Market: By Route of Administration, 2021-2031, USD (Million)
  • 12.4. Anti-Infective Drugs Market: By Indication, 2021-2031, USD (Million)
  • 12.5. Anti-Infective Drugs Market: By Distribution Channel, 2021-2031, USD (Million)
  • 12.6.Anti-Infective Drugs Market: By Region, 2021-2031, USD (Million)
    • 12.6.1.Latin America
      • 12.6.1.1. Brazil
        • 12.6.1.1.1. Anti-Infective Drugs Market: By Drug Class, 2021-2031, USD (Million)
        • 12.6.1.1.2. Anti-Infective Drugs Market: By Route of Administration, 2021-2031, USD (Million)
        • 12.6.1.1.3. Anti-Infective Drugs Market: By Indication, 2021-2031, USD (Million)
        • 12.6.1.1.4. Anti-Infective Drugs Market: By Distribution Channel, 2021-2031, USD (Million)
      • 12.6.1.2. Mexico
        • 12.6.1.2.1. Anti-Infective Drugs Market: By Drug Class, 2021-2031, USD (Million)
        • 12.6.1.2.2. Anti-Infective Drugs Market: By Route of Administration, 2021-2031, USD (Million)
        • 12.6.1.2.3. Anti-Infective Drugs Market: By Indication, 2021-2031, USD (Million)
        • 12.6.1.2.4. Anti-Infective Drugs Market: By Distribution Channel, 2021-2031, USD (Million)
      • 12.6.1.3. Rest of Latin America
        • 12.6.1.3.1. Anti-Infective Drugs Market: By Drug Class, 2021-2031, USD (Million)
        • 12.6.1.3.2. Anti-Infective Drugs Market: By Route of Administration, 2021-2031, USD (Million)
        • 12.6.1.3.3. Anti-Infective Drugs Market: By Indication, 2021-2031, USD (Million)
        • 12.6.1.3.4. Anti-Infective Drugs Market: By Distribution Channel, 2021-2031, USD (Million)

13. Middle East and Africa Anti-Infective Drugs Market, 2021-2031, USD (Million)

  • 13.1. Market Overview
  • 13.2. Anti-Infective Drugs Market: By Drug Class, 2021-2031, USD (Million)
  • 13.3. Anti-Infective Drugs Market: By Route of Administration, 2021-2031, USD (Million)
  • 13.4. Anti-Infective Drugs Market: By Indication, 2021-2031, USD (Million)
  • 13.5. Anti-Infective Drugs Market: By Distribution Channel, 2021-2031, USD (Million)
  • 13.6.Anti-Infective Drugs Market: By Region, 2021-2031, USD (Million)
    • 13.6.1.Middle East and Africa
      • 13.6.1.1. GCC
        • 13.6.1.1.1. Anti-Infective Drugs Market: By Drug Class, 2021-2031, USD (Million)
        • 13.6.1.1.2. Anti-Infective Drugs Market: By Route of Administration, 2021-2031, USD (Million)
        • 13.6.1.1.3. Anti-Infective Drugs Market: By Indication, 2021-2031, USD (Million)
        • 13.6.1.1.4. Anti-Infective Drugs Market: By Distribution Channel, 2021-2031, USD (Million)
      • 13.6.1.2. Africa
        • 13.6.1.2.1. Anti-Infective Drugs Market: By Drug Class, 2021-2031, USD (Million)
        • 13.6.1.2.2. Anti-Infective Drugs Market: By Route of Administration, 2021-2031, USD (Million)
        • 13.6.1.2.3. Anti-Infective Drugs Market: By Indication, 2021-2031, USD (Million)
        • 13.6.1.2.4. Anti-Infective Drugs Market: By Distribution Channel, 2021-2031, USD (Million)
      • 13.6.1.3. Rest of Middle East and Africa
        • 13.6.1.3.1. Anti-Infective Drugs Market: By Drug Class, 2021-2031, USD (Million)
        • 13.6.1.3.2. Anti-Infective Drugs Market: By Route of Administration, 2021-2031, USD (Million)
        • 13.6.1.3.3. Anti-Infective Drugs Market: By Indication, 2021-2031, USD (Million)
        • 13.6.1.3.4. Anti-Infective Drugs Market: By Distribution Channel, 2021-2031, USD (Million)

14. Company Profile

  • 14.1. Pfizer Inc.
    • 14.1.1. Company Overview
    • 14.1.2. Financial Performance
    • 14.1.3. Product Portfolio
    • 14.1.4. Strategic Initiatives
  • 14.2. GlaxoSmithKline plc
    • 14.2.1. Company Overview
    • 14.2.2. Financial Performance
    • 14.2.3. Product Portfolio
    • 14.2.4. Strategic Initiatives
  • 14.3. Merck & Co. Inc.
    • 14.3.1. Company Overview
    • 14.3.2. Financial Performance
    • 14.3.3. Product Portfolio
    • 14.3.4. Strategic Initiatives
  • 14.4. Novartis AG
    • 14.4.1. Company Overview
    • 14.4.2. Financial Performance
    • 14.4.3. Product Portfolio
    • 14.4.4. Strategic Initiatives
  • 14.5. Johnson & Johnson
    • 14.5.1. Company Overview
    • 14.5.2. Financial Performance
    • 14.5.3. Product Portfolio
    • 14.5.4. Strategic Initiatives
  • 14.6. Gland Pharma Ltd.
    • 14.6.1. Company Overview
    • 14.6.2. Financial Performance
    • 14.6.3. Product Portfolio
    • 14.6.4. Strategic Initiatives
  • 14.7. Teva Pharmaceutical Industries Ltd.
    • 14.7.1. Company Overview
    • 14.7.2. Financial Performance
    • 14.7.3. Product Portfolio
    • 14.7.4. Strategic Initiatives
  • 14.8. F. Hoffmann-La Roche Ltd.
    • 14.8.1. Company Overview
    • 14.8.2. Financial Performance
    • 14.8.3. Product Portfolio
    • 14.8.4. Strategic Initiatives
  • 14.9. Gilead Sciences, Inc.
    • 14.9.1. Company Overview
    • 14.9.2. Financial Performance
    • 14.9.3. Product Portfolio
    • 14.9.4. Strategic Initiatives
  • 14.10. Abbott
    • 14.10.1. Company Overview
    • 14.10.2. Financial Performance
    • 14.10.3. Product Portfolio
    • 14.10.4. Strategic Initiatives
  • 14.11. Astellas Pharma Inc.
    • 14.11.1. Company Overview
    • 14.11.2. Financial Performance
    • 14.11.3. Product Portfolio
    • 14.11.4. Strategic Initiatives
  • 14.12. Alkem Laboratories
    • 14.12.1. Company Overview
    • 14.12.2. Financial Performance
    • 14.12.3. Product Portfolio
    • 14.12.4. Strategic Initiatives
  • 14.13. AstraZeneca
    • 14.13.1. Company Overview
    • 14.13.2. Financial Performance
    • 14.13.3. Product Portfolio
    • 14.13.4. Strategic Initiatives
  • 14.14. Eli Lilly and Company
    • 14.14.1. Company Overview
    • 14.14.2. Financial Performance
    • 14.14.3. Product Portfolio
    • 14.14.4. Strategic Initiatives
  • 14.15. Takeda Pharmaceutical Company Limited
    • 14.15.1. Company Overview
    • 14.15.2. Financial Performance
    • 14.15.3. Product Portfolio
    • 14.15.4. Strategic Initiatives
  • 14.16. Sanofi
    • 14.16.1. Company Overview
    • 14.16.2. Financial Performance
    • 14.16.3. Product Portfolio
    • 14.16.4. Strategic Initiatives
  • 14.17. Other Notable Players
    • 14.17.1. Company Overview
    • 14.17.2. Financial Performance
    • 14.17.3. Product Portfolio
    • 14.17.4. Strategic Initiatives
Product Code: 138243-07-23

List of Tables

  • TABLE 1 Global Anti-Infective Drugs Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 2 Global Anti-Infective Drugs Market By Antibacterials, 2021-2031, USD (Million)

TABLE 3 Global Anti-Infective Drugs Market By Antivirals, 2021-2031, USD (Million)

TABLE 4 Global Anti-Infective Drugs Market By Antifungals, 2021-2031, USD (Million)

TABLE 5 Global Anti-Infective Drugs Market By Route of Administration, 2021-2031, USD (Million)

  • TABLE 6 Global Anti-Infective Drugs Market By Indication, 2021-2031, USD (Million)
  • TABLE 7 Global Anti-Infective Drugs Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 8 North America Anti-Infective Drugs Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 9 North America Anti-Infective Drugs Market By Antibacterials, 2021-2031, USD (Million)

TABLE 10 North America Anti-Infective Drugs Market By Antivirals, 2021-2031, USD (Million)

TABLE 11 North America Anti-Infective Drugs Market By Antifungals, 2021-2031, USD (Million)

TABLE 12 North America Anti-Infective Drugs Market By Route of Administration, 2021-2031, USD (Million)

  • TABLE 13 North America Anti-Infective Drugs Market By Indication, 2021-2031, USD (Million)
  • TABLE 14 North America Anti-Infective Drugs Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 15 U.S. Anti-Infective Drugs Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 16 U.S. Anti-Infective Drugs Market By Antibacterials, 2021-2031, USD (Million)

TABLE 17 U.S. Anti-Infective Drugs Market By Antivirals, 2021-2031, USD (Million)

TABLE 18 U.S. Anti-Infective Drugs Market By Antifungals, 2021-2031, USD (Million)

TABLE 19 U.S. Anti-Infective Drugs Market By Route of Administration, 2021-2031, USD (Million)

  • TABLE 20 U.S. Anti-Infective Drugs Market By Indication, 2021-2031, USD (Million)
  • TABLE 21 U.S. Anti-Infective Drugs Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 22 Canada Anti-Infective Drugs Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 23 Canada Anti-Infective Drugs Market By Antibacterials, 2021-2031, USD (Million)

TABLE 24 Canada Anti-Infective Drugs Market By Antivirals, 2021-2031, USD (Million)

TABLE 25 Canada Anti-Infective Drugs Market By Antifungals, 2021-2031, USD (Million)

TABLE 26 Canada Anti-Infective Drugs Market By Route of Administration, 2021-2031, USD (Million)

  • TABLE 27 Canada Anti-Infective Drugs Market By Indication, 2021-2031, USD (Million)
  • TABLE 28 Canada Anti-Infective Drugs Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 29 Rest of North America Anti-Infective Drugs Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 30 Rest of North America Anti-Infective Drugs Market By Antibacterials, 2021-2031, USD (Million)

TABLE 31 Rest of North America Anti-Infective Drugs Market By Antivirals, 2021-2031, USD (Million)

TABLE 32 Rest of North America Anti-Infective Drugs Market By Antifungals, 2021-2031, USD (Million)

TABLE 33 Rest of North America Anti-Infective Drugs Market By Route of Administration, 2021-2031, USD (Million)

  • TABLE 34 Rest of North America Anti-Infective Drugs Market By Indication, 2021-2031, USD (Million)
  • TABLE 35 Rest of North America Anti-Infective Drugs Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 36 UK and European Union Anti-Infective Drugs Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 37 UK and European Union Anti-Infective Drugs Market By Antibacterials, 2021-2031, USD (Million)

TABLE 38 UK and European Union Anti-Infective Drugs Market By Antivirals, 2021-2031, USD (Million)

TABLE 39 UK and European Union Anti-Infective Drugs Market By Antifungals, 2021-2031, USD (Million)

TABLE 40 UK and European Union Anti-Infective Drugs Market By Route of Administration, 2021-2031, USD (Million)

  • TABLE 41 UK and European Union Anti-Infective Drugs Market By Indication, 2021-2031, USD (Million)
  • TABLE 42 UK and European Union Anti-Infective Drugs Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 43 UK Anti-Infective Drugs Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 44 UK Anti-Infective Drugs Market By Antibacterials, 2021-2031, USD (Million)

TABLE 45 UK Anti-Infective Drugs Market By Antivirals, 2021-2031, USD (Million)

TABLE 46 UK Anti-Infective Drugs Market By Antifungals, 2021-2031, USD (Million)

TABLE 47 UK Anti-Infective Drugs Market By Route of Administration, 2021-2031, USD (Million)

  • TABLE 48 UK Anti-Infective Drugs Market By Indication, 2021-2031, USD (Million)
  • TABLE 49 UK Anti-Infective Drugs Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 50 Germany Anti-Infective Drugs Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 51 Germany Anti-Infective Drugs Market By Antibacterials, 2021-2031, USD (Million)

TABLE 52 Germany Anti-Infective Drugs Market By Antivirals, 2021-2031, USD (Million)

TABLE 53 Germany Anti-Infective Drugs Market By Antifungals, 2021-2031, USD (Million)

TABLE 54 Germany Anti-Infective Drugs Market By Route of Administration, 2021-2031, USD (Million)

  • TABLE 55 Germany Anti-Infective Drugs Market By Indication, 2021-2031, USD (Million)
  • TABLE 56 Germany Anti-Infective Drugs Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 57 Spain Anti-Infective Drugs Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 58 Spain Anti-Infective Drugs Market By Antibacterials, 2021-2031, USD (Million)

TABLE 59 Spain Anti-Infective Drugs Market By Antivirals, 2021-2031, USD (Million)

TABLE 60 Spain Anti-Infective Drugs Market By Antifungals, 2021-2031, USD (Million)

TABLE 61 Spain Anti-Infective Drugs Market By Route of Administration, 2021-2031, USD (Million)

  • TABLE 62 Spain Anti-Infective Drugs Market By Indication, 2021-2031, USD (Million)
  • TABLE 63 Spain Anti-Infective Drugs Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 64 Italy Anti-Infective Drugs Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 65 Italy Anti-Infective Drugs Market By Antibacterials, 2021-2031, USD (Million)

TABLE 66 Italy Anti-Infective Drugs Market By Antivirals, 2021-2031, USD (Million)

TABLE 67 Italy Anti-Infective Drugs Market By Antifungals, 2021-2031, USD (Million)

TABLE 68 Italy Anti-Infective Drugs Market By Route of Administration, 2021-2031, USD (Million)

  • TABLE 69 Italy Anti-Infective Drugs Market By Indication, 2021-2031, USD (Million)
  • TABLE 70 Italy Anti-Infective Drugs Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 71 France Anti-Infective Drugs Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 72 France Anti-Infective Drugs Market By Antibacterials, 2021-2031, USD (Million)

TABLE 73 France Anti-Infective Drugs Market By Antivirals, 2021-2031, USD (Million)

TABLE 74 France Anti-Infective Drugs Market By Antifungals, 2021-2031, USD (Million)

TABLE 75 France Anti-Infective Drugs Market By Route of Administration, 2021-2031, USD (Million)

  • TABLE 76 France Anti-Infective Drugs Market By Indication, 2021-2031, USD (Million)
  • TABLE 77 France Anti-Infective Drugs Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 78 Rest of Europe Anti-Infective Drugs Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 79 Rest of Europe Anti-Infective Drugs Market By Antibacterials, 2021-2031, USD (Million)

TABLE 80 Rest of Europe Anti-Infective Drugs Market By Antivirals, 2021-2031, USD (Million)

TABLE 81 Rest of Europe Anti-Infective Drugs Market By Antifungals, 2021-2031, USD (Million)

TABLE 82 Rest of Europe Anti-Infective Drugs Market By Route of Administration, 2021-2031, USD (Million)

  • TABLE 83 Rest of Europe Anti-Infective Drugs Market By Indication, 2021-2031, USD (Million)
  • TABLE 84 Rest of Europe Anti-Infective Drugs Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 85 Asia Anti-Infective Drugs Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 86 Asia Anti-Infective Drugs Market By Antibacterials, 2021-2031, USD (Million)

TABLE 87 Asia Anti-Infective Drugs Market By Antivirals, 2021-2031, USD (Million)

TABLE 88 Asia Anti-Infective Drugs Market By Antifungals, 2021-2031, USD (Million)

TABLE 89 Asia Anti-Infective Drugs Market By Route of Administration, 2021-2031, USD (Million)

  • TABLE 90 Asia Anti-Infective Drugs Market By Indication, 2021-2031, USD (Million)
  • TABLE 91 Asia Anti-Infective Drugs Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 92 China Anti-Infective Drugs Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 93 China Anti-Infective Drugs Market By Antibacterials, 2021-2031, USD (Million)

TABLE 94 China Anti-Infective Drugs Market By Antivirals, 2021-2031, USD (Million)

TABLE 95 China Anti-Infective Drugs Market By Antifungals, 2021-2031, USD (Million)

TABLE 96 China Anti-Infective Drugs Market By Route of Administration, 2021-2031, USD (Million)

  • TABLE 97 China Anti-Infective Drugs Market By Indication, 2021-2031, USD (Million)
  • TABLE 98 China Anti-Infective Drugs Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 99 Japan Anti-Infective Drugs Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 100 Japan Anti-Infective Drugs Market By Antibacterials, 2021-2031, USD (Million)

TABLE 101 Japan Anti-Infective Drugs Market By Antivirals, 2021-2031, USD (Million)

TABLE 102 Japan Anti-Infective Drugs Market By Antifungals, 2021-2031, USD (Million)

TABLE 103 Japan Anti-Infective Drugs Market By Route of Administration, 2021-2031, USD (Million)

  • TABLE 104 Japan Anti-Infective Drugs Market By Indication, 2021-2031, USD (Million)
  • TABLE 105 Japan Anti-Infective Drugs Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 106 India Anti-Infective Drugs Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 107 India Anti-Infective Drugs Market By Antibacterials, 2021-2031, USD (Million)

TABLE 108 India Anti-Infective Drugs Market By Antivirals, 2021-2031, USD (Million)

TABLE 109 India Anti-Infective Drugs Market By Antifungals, 2021-2031, USD (Million)

TABLE 110 India Anti-Infective Drugs Market By Route of Administration, 2021-2031, USD (Million)

  • TABLE 111 India Anti-Infective Drugs Market By Indication, 2021-2031, USD (Million)
  • TABLE 112 India Anti-Infective Drugs Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 113 Australia Anti-Infective Drugs Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 114 Australia Anti-Infective Drugs Market By Antibacterials, 2021-2031, USD (Million)

TABLE 115 Australia Anti-Infective Drugs Market By Antivirals, 2021-2031, USD (Million)

TABLE 116 Australia Anti-Infective Drugs Market By Antifungals, 2021-2031, USD (Million)

TABLE 117 Australia Anti-Infective Drugs Market By Route of Administration, 2021-2031, USD (Million)

  • TABLE 118 Australia Anti-Infective Drugs Market By Indication, 2021-2031, USD (Million)
  • TABLE 119 Australia Anti-Infective Drugs Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 120 South Korea Anti-Infective Drugs Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 121 South Korea Anti-Infective Drugs Market By Antibacterials, 2021-2031, USD (Million)

TABLE 122 South Korea Anti-Infective Drugs Market By Antivirals, 2021-2031, USD (Million)

TABLE 123 South Korea Anti-Infective Drugs Market By Antifungals, 2021-2031, USD (Million)

TABLE 124 South Korea Anti-Infective Drugs Market By Route of Administration, 2021-2031, USD (Million)

  • TABLE 125 South Korea Anti-Infective Drugs Market By Indication, 2021-2031, USD (Million)
  • TABLE 126 South Korea Anti-Infective Drugs Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 127 Latin America Anti-Infective Drugs Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 128 Latin America Anti-Infective Drugs Market By Antibacterials, 2021-2031, USD (Million)

TABLE 129 Latin America Anti-Infective Drugs Market By Antivirals, 2021-2031, USD (Million)

TABLE 130 Latin America Anti-Infective Drugs Market By Antifungals, 2021-2031, USD (Million)

TABLE 131 Latin America Anti-Infective Drugs Market By Route of Administration, 2021-2031, USD (Million)

  • TABLE 132 Latin America Anti-Infective Drugs Market By Indication, 2021-2031, USD (Million)
  • TABLE 133 Latin America Anti-Infective Drugs Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 134 Brazil Anti-Infective Drugs Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 135 Brazil Anti-Infective Drugs Market By Antibacterials, 2021-2031, USD (Million)

TABLE 136 Brazil Anti-Infective Drugs Market By Antivirals, 2021-2031, USD (Million)

TABLE 137 Brazil Anti-Infective Drugs Market By Antifungals, 2021-2031, USD (Million)

TABLE 138 Brazil Anti-Infective Drugs Market By Route of Administration, 2021-2031, USD (Million)

  • TABLE 139 Brazil Anti-Infective Drugs Market By Indication, 2021-2031, USD (Million)
  • TABLE 140 Brazil Anti-Infective Drugs Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 141 Mexico Anti-Infective Drugs Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 142 Mexico Anti-Infective Drugs Market By Antibacterials, 2021-2031, USD (Million)

TABLE 143 Mexico Anti-Infective Drugs Market By Antivirals, 2021-2031, USD (Million)

TABLE 144 Mexico Anti-Infective Drugs Market By Antifungals, 2021-2031, USD (Million)

TABLE 145 Mexico Anti-Infective Drugs Market By Route of Administration, 2021-2031, USD (Million)

  • TABLE 146 Mexico Anti-Infective Drugs Market By Indication, 2021-2031, USD (Million)
  • TABLE 147 Mexico Anti-Infective Drugs Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 148 Rest of Latin America Anti-Infective Drugs Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 149 Rest of Latin America Anti-Infective Drugs Market By Antibacterials, 2021-2031, USD (Million)

TABLE 150 Rest of Latin America Anti-Infective Drugs Market By Antivirals, 2021-2031, USD (Million)

TABLE 151 Rest of Latin America Anti-Infective Drugs Market By Antifungals, 2021-2031, USD (Million)

TABLE 152 Rest of Latin America Anti-Infective Drugs Market By Route of Administration, 2021-2031, USD (Million)

  • TABLE 153 Rest of Latin America Anti-Infective Drugs Market By Indication, 2021-2031, USD (Million)
  • TABLE 154 Rest of Latin America Anti-Infective Drugs Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 155 Middle East and Africa Anti-Infective Drugs Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 156 Middle East and Africa Anti-Infective Drugs Market By Antibacterials, 2021-2031, USD (Million)

TABLE 157 Middle East and Africa Anti-Infective Drugs Market By Antivirals, 2021-2031, USD (Million)

TABLE 158 Middle East and Africa Anti-Infective Drugs Market By Antifungals, 2021-2031, USD (Million)

TABLE 159 Middle East and Africa Anti-Infective Drugs Market By Route of Administration, 2021-2031, USD (Million)

  • TABLE 160 Middle East and Africa Anti-Infective Drugs Market By Indication, 2021-2031, USD (Million)
  • TABLE 161 Middle East and Africa Anti-Infective Drugs Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 162 GCC Anti-Infective Drugs Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 163 GCC Anti-Infective Drugs Market By Antibacterials, 2021-2031, USD (Million)

TABLE 164 GCC Anti-Infective Drugs Market By Antivirals, 2021-2031, USD (Million)

TABLE 165 GCC Anti-Infective Drugs Market By Antifungals, 2021-2031, USD (Million)

TABLE 166 GCC Anti-Infective Drugs Market By Route of Administration, 2021-2031, USD (Million)

  • TABLE 167 GCC Anti-Infective Drugs Market By Indication, 2021-2031, USD (Million)
  • TABLE 168 GCC Anti-Infective Drugs Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 169 Africa Anti-Infective Drugs Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 170 Africa Anti-Infective Drugs Market By Antibacterials, 2021-2031, USD (Million)

TABLE 171 Africa Anti-Infective Drugs Market By Antivirals, 2021-2031, USD (Million)

TABLE 172 Africa Anti-Infective Drugs Market By Antifungals, 2021-2031, USD (Million)

TABLE 173 Africa Anti-Infective Drugs Market By Route of Administration, 2021-2031, USD (Million)

  • TABLE 174 Africa Anti-Infective Drugs Market By Indication, 2021-2031, USD (Million)
  • TABLE 175 Africa Anti-Infective Drugs Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 176 Rest of Middle East and Africa Anti-Infective Drugs Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 177 Rest of Middle East and Africa Anti-Infective Drugs Market By Antibacterials, 2021-2031, USD (Million)

TABLE 178 Rest of Middle East and Africa Anti-Infective Drugs Market By Antivirals, 2021-2031, USD (Million)

TABLE 179 Rest of Middle East and Africa Anti-Infective Drugs Market By Antifungals, 2021-2031, USD (Million)

TABLE 180 Rest of Middle East and Africa Anti-Infective Drugs Market By Route of Administration, 2021-2031, USD (Million)

  • TABLE 181 Rest of Middle East and Africa Anti-Infective Drugs Market By Indication, 2021-2031, USD (Million)
  • TABLE 182 Rest of Middle East and Africa Anti-Infective Drugs Market By Distribution Channel, 2021-2031, USD (Million)

List of Figures

  • FIG. 1 Global Anti-Infective Drugs Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Anti-Infective Drugs Market: Quality Assurance
  • FIG. 5 Global Anti-Infective Drugs Market, By Drug Class, 2022
  • FIG. 6 Global Anti-Infective Drugs Market, By Route of Administration, 2022
  • FIG. 7 Global Anti-Infective Drugs Market, By Indication, 2022
  • FIG. 8 Global Anti-Infective Drugs Market, By Distribution Channel, 2022
  • FIG. 9 Global Anti-Infective Drugs Market, By Geography, 2022
  • FIG. 10 Market Geographical Opportunity Matrix - Global Anti-Infective Drugs Market, 2022

FIG. 11Market Positioning of Key Anti-Infective Drugs Market Players, 2022

FIG. 12Global Anti-Infective Drugs Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031

  • FIG. 13 Global Anti-Infective Drugs Market, By Drug Class, 2022 Vs 2031, %
  • FIG. 14 Global Anti-Infective Drugs Market, By Route of Administration, 2022 Vs 2031, %
  • FIG. 15 Global Anti-Infective Drugs Market, By Indication, 2022 Vs 2031, %
  • FIG. 16 Global Anti-Infective Drugs Market, By Distribution Channel, 2022 Vs 2031, %
  • FIG. 17 U.S. Anti-Infective Drugs Market (US$ Million), 2021 - 2031
  • FIG. 18 Canada Anti-Infective Drugs Market (US$ Million), 2021 - 2031
  • FIG. 19 Rest of North America Anti-Infective Drugs Market (US$ Million), 2021 - 2031
  • FIG. 20 UK Anti-Infective Drugs Market (US$ Million), 2021 - 2031
  • FIG. 21 Germany Anti-Infective Drugs Market (US$ Million), 2021 - 2031
  • FIG. 22 Spain Anti-Infective Drugs Market (US$ Million), 2021 - 2031
  • FIG. 23 Italy Anti-Infective Drugs Market (US$ Million), 2021 - 2031
  • FIG. 24 France Anti-Infective Drugs Market (US$ Million), 2021 - 2031
  • FIG. 25 Rest of Europe Anti-Infective Drugs Market (US$ Million), 2021 - 2031
  • FIG. 26 China Anti-Infective Drugs Market (US$ Million), 2021 - 2031
  • FIG. 27 Japan Anti-Infective Drugs Market (US$ Million), 2021 - 2031
  • FIG. 28 India Anti-Infective Drugs Market (US$ Million), 2021 - 2031
  • FIG. 29 Australia Anti-Infective Drugs Market (US$ Million), 2021 - 2031
  • FIG. 30 South Korea Anti-Infective Drugs Market (US$ Million), 2021 - 2031
  • FIG. 31 Rest of Asia Anti-Infective Drugs Market (US$ Million), 2021 - 2031
  • FIG. 32 Brazil Anti-Infective Drugs Market (US$ Million), 2021 - 2031
  • FIG. 33 Mexico Anti-Infective Drugs Market (US$ Million), 2021 - 2031
  • FIG. 34 Rest of Latin America Anti-Infective Drugs Market (US$ Million), 2021 - 2031
  • FIG. 35 GCC Anti-Infective Drugs Market (US$ Million), 2021 - 2031
  • FIG. 36 Africa Anti-Infective Drugs Market (US$ Million), 2021 - 2031
  • FIG. 37 Rest of Middle East and Africa Anti-Infective Drugs Market (US$ Million), 2021 - 2031
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!